Tag Archive | "phase III"

Ophthotech in $85 million IPO financing

Tags: , , ,

Ophthotech has entered into an IPO financing round in the hope of raising up to $85 million. Read the full story

Quest Diagnostics pharma deals Royalty pharma for Ibrutinib

Tags: , ,

Quest Diagnostics has completed the sale of its rights to royalties from commercialization of the drug candidate ibrutinib to Royalty Pharma for $485 million in cash, as part of pharma deals. Read the full story

Ophthotech in $175 million Royalty and series C financing deal

Tags: , ,

Ophthotech, biotech company, announced that it has raised $175 million in royalty and series C financing for a global Phase III clinical program. Read the full story

Auris Medical secures $50.6 million in Series C financing

Tags: , , ,

Auris Medical secures $50.6 Million in Series C financing deal. Read the full story

Pfizer receives backing for late-stage trial of kidney cancer drug in Asia

Tags: , , ,

SFJ Pharma has entered into a collaborative development agreement with Pfizer to conduct a Phase 3 clinical trial in Asia of Pfizer's investigational agent axitinib for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy.  Read the full story

Eisai enters into co-promotion agreement with Novartis for COPD therapies

Tags: , , , , ,

Eisai has entered into a Japan co-promotion agreement with Novartis Pharma K.K. for three Novartis Pharma therapies for chronic obstructive pulmonary disease (COPD).  Read the full story

Intercell and Merck dump Phase II/III vaccine study

Tags: , , , , ,

Two months after Intercell CEO Gerd Zettlmeissl insisted that the decision to halt patient recruitment for a Phase II/III trial of its experimental vaccine V710 did not signal the end of the program--and a month after Zettlmeissl unceremoniously departed from the helm-- Read the full story

Clinical Stage Partnering Terms and Agreements in Pharma and Biotech

Tags: , , , , , , , ,

The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the clinical stage agreements entered into by the worlds leading biopharma companies.

Read the full story